IMUNON to Hold First Quarter 2023 Financial Results and Business Update Conference Call on Thursday, May 11, 2023
04 Mayo 2023 - 7:30AM
IMUNON, Inc. (NASDAQ:
IMNN), a clinical-stage drug-development company focused
on developing DNA-mediated immunotherapy and next-generation
vaccines, announces that the Company will host a conference call at
11:00 a.m. EDT on Thursday, May 11, 2023 to discuss financial
results for the first quarter ended March 31, 2023 and provide an
update on its clinical development of IMNN-001, a DNA-based
interleukin-12 (IL-12) immunotherapy in Phase 2 clinical
development for the treatment of advanced-stage ovarian cancer, and
its preclinical studies of PLACCINE, a proprietary, multivalent
DNA-based plasmid technology utilizing synthetic, non-viral
delivery vectors, being evaluated in proof-of-concept studies for
superiority over current mRNA vaccines.
To participate in the call, interested parties
may dial 866-777-2509 (Toll-Free/North America) or 412-317-5413
(International/Toll) and ask for the IMUNON, Inc. First Quarter
2023 Earnings Call. A live webcast of the call will be available
here.
The call will be archived for replay
until May 25, 2023 and can be accessed at 877-344-7529 (U.S.
Toll-Free), 855-669-9658 (Canada Toll-Free) or 412-317-0088
(International Toll), using the replay access code 6902750. An
audio replay of the call will also be available here for 90
days.
About IMUNON
IMUNON is a fully integrated, clinical stage
biotechnology company focused on advancing a portfolio of
innovative treatments that harness the body’s natural mechanisms to
generate safe, effective and durable responses across a broad array
of human diseases, constituting a differentiating approach from
conventional therapies.
IMUNON has two platform technologies: the
TheraPlas modality for the development of immunotherapies and other
anti-cancer nucleic acid-based therapies, and the PLACCINE modality
for the development of nucleic acid vaccines for infectious
diseases and cancer. The company’s lead clinical program, IMNN-001,
is a DNA-based immunotherapy for the localized treatment of
advanced ovarian cancer currently in Phase 2 development. IMNN-001
works by instructing the body to produce safe and durable levels of
powerful cancer-fighting molecules, such as interleukin-12 and
interferon gamma, at the tumor site. Additionally, the company is
conducting preclinical proof-of-concept studies on a nucleic acid
vaccine candidate targeting the SARS-CoV-2 virus to validate its
PLACCINE platform. IMUNON’s platform technologies are based on the
delivery of nucleic acids with novel synthetic delivery systems
that are independent of viral vectors or devices. IMUNON will
continue to leverage these platforms and to advance the
technological frontier of nucleic acid-based products to better
serve patients with difficult-to-treat conditions. For more
information on IMUNON, visit www.imunon.com.
Forward-Looking Statements
IMUNON wishes to inform readers that
forward-looking statements in this news release are made pursuant
to the “safe harbor” provisions of the Private Securities
Litigation Reform Act of 1995. Readers are cautioned that such
forward-looking statements involve risks and uncertainties
including, without limitation, unforeseen changes in the course of
research and development activities and in clinical trials; the
uncertainties of and difficulties in analyzing interim clinical
data; the significant expense, time and risk of failure of
conducting clinical trials; the need for IMUNON to evaluate its
future development plans; possible acquisitions or licenses of
other technologies, assets or businesses; possible actions by
customers, suppliers, competitors or regulatory authorities; and
other risks detailed from time to time in IMUNON’s periodic reports
and prospectuses filed with the Securities and Exchange Commission.
IMUNON assumes no obligation to update or supplement
forward-looking statements that become untrue because of subsequent
events, new information or otherwise.
Contacts:
IMUNON |
LHA Investor Relations |
Jeffrey W. Church |
Kim Sutton Golodetz |
Executive Vice President, CFO |
212-838-3777 |
and Corporate Secretary |
Kgolodetz@lhai.com |
609-482-2455 |
|
jchurch@imunon.com |
|
# # #
Imunon (NASDAQ:IMNN)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Imunon (NASDAQ:IMNN)
Gráfica de Acción Histórica
De May 2023 a May 2024